PubMed Health⌕ Search

PubMed · 16331940

Density functional studies of actinyl aquo complexes studied using small-core effective core potentials and a scalar four-component relativistic method.

Abstract

The title compounds, [AnO(2)(H(2)O)(5)](n)(+), n = 1 or 2 and An = U, Np, and Pu, are studied using relativistic density functional theory (DFT). Three rather different relativistic methods are used, small-core effective core potentials (SC-ECP), a scalar four-component all-electron relativistic method, and the zeroeth-order regular approximation. The methods provide similar results for a variety of properties, giving confidence in their accuracy. Spin-orbit and multiplet corrections to the An(VI)/An(V) reduction potential are added in an approximate fashion but are found to be essential. Bulk solvation effects are modeled with continuum solvation models (CPCM, COSMO). These models are tested by comparing explicit (cluster), continuum, and mixed cluster/continuum solvation models as applied to various properties. The continuum solvation models are shown to accurately account for the effects of the solvent, provided that at least the first coordination sphere is included. Reoptimizing the structures in the presence of the bulk solvent is seen to be important for the equatorial bond lengths but less relevant for energetics. Explicit inclusion of waters in the second coordination sphere has a modest influence on the energetics. For the first time, free energies of solvation are calculated for all six [AnO(2)(H(2)O)(5)](n)(+) species. The calculated numbers are within the experimental error margins, and the experimental trend is reproduced correctly. By comparison of different relativistic methods, it is shown that an accurate relativistic description leads to marked improvements over the older large-core ECP (LC-ECP) method for bond lengths, vibrational frequencies, and, in particular, the An(VI)/An(V) reduction potential. Two approximate DFT methods are compared, B3LYP, a hybrid DFT method, and PBE, a generalized gradient approximation. Either method yields An(VI)/An(V) reduction potentials of comparable quality. Overall, the experimental reduction potentials are accurately reproduced by the calculations.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Grigory A Shamov, Georg Schreckenbach. 2005-12-08. Density functional studies of actinyl aquo complexes studied using small-core effective core potentials and a scalar four-component relativistic method.. https://doi.org/10.1021/jp053522f

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗